A liquid biopsy signature predicts treatment response to fluoropyrimidine plus platinum therapy in patients with metastatic or unresectable gastric cancer: implications for precision oncology

Mol Cancer. 2022 Jan 3;21(1):9. doi: 10.1186/s12943-021-01483-8.

In-Seob Lee^{1

2}, Zhongxu Zhu³, Jeeyun Lee⁴, Joon Oh Park⁴, Xiwei Wu⁵, Tiffany Ong⁶, Sierra Min Li⁶, Xin Wang³, Joseph Chao^#⁷, Ajay Goel^#^{8

9}

¹ Department of Molecular Diagnostics and Experimental Therapeutics, Beckman Research Institute of City of Hope, Biomedical Research Center, Comprehensive Cancer Center, 1218 S. Fifth Avenue, Monrovia, CA, 91016, USA.
² Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
³ Department of Biomedical Sciences, City University of Hong Kong, Hong Kong, China.
⁴ Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
⁵ Integrative Genomics Core, Beckman Research Institute of City of Hope, Duarte, CA, USA.
⁶ Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, 1500 E. Duarte Road, Duarte, CA, 91010, USA.
⁷ Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, 1500 E. Duarte Road, Duarte, CA, 91010, USA. jchao@coh.org.
⁸ Department of Molecular Diagnostics and Experimental Therapeutics, Beckman Research Institute of City of Hope, Biomedical Research Center, Comprehensive Cancer Center, 1218 S. Fifth Avenue, Monrovia, CA, 91016, USA. ajgoel@coh.org.
⁹ City of Hope Comprehensive Cancer Center, Duarte, CA, USA. ajgoel@coh.org.

^# Contributed equally.

No abstract available

Publication types